Home >> Top News >> Roche launches Navify Mutation Profiler, Therapy Matcher

Roche launches Navify Mutation Profiler, Therapy Matcher

Print Friendly, PDF & Email

March 27, 2019—Roche announced the CE-IVD mark and launch of its Navify Mutation Profiler, clinical software that provides annotation, interpretation, and clinical reporting of next-generation sequencing tests. Roche launched also its Navify Therapy Matcher, an optional clinical decision support app that further aids clinicians in linking clinically actionable mutations to relevant therapy options.

Navify Mutation Profiler simplifies how labs report on their NGS tests, according to Roche.

Navify Mutation Profiler and Navify Therapy Matcher together offer a “clinical decision support solution that addresses a major workflow challenge for NGS labs, synthesizing large amounts of medical and scientific data into actionable insights,” Neil Gunn, head of Roche Sequencing Solutions, said in a statement.


Check Also

Roche’s Xofluza approved for influenza treatment

February 2019—Roche announced that the FDA has approved Xofluza (baloxavir marboxil) for the treatment of acute, uncomplicated influenza in people 12 years of age and older. Xofluza is a single-dose oral medicine with a novel proposed mechanism of action that inhibits polymerase acidic endonuclease.